SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma.

Belada, D; Georgiev, P; Dakhil, S; Inhorn, LF; Andorsky, D; Beck, JT; Quick, D; Pettengell, R; Daly, R; Dean, JP; et al. Belada, D; Georgiev, P; Dakhil, S; Inhorn, LF; Andorsky, D; Beck, JT; Quick, D; Pettengell, R; Daly, R; Dean, JP; Pavlyuk, M; Failloux, N; Hübel, K (2016) Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma. Future Oncology, 12 (15). pp. 1759-1768. ISSN 1744-8301 https://doi.org/10.2217/fon-2016-0137
SGUL Authors: Pettengell, Ruth

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (1MB) | Preview

Abstract

UNLABELLED: We describe the rationale and design of the ongoing randomized, active-controlled, multicenter, Phase III study evaluating the efficacy of pixantrone and rituximab versus gemcitabine and rituximab in patients with diffuse large B-cell lymphoma or follicular grade 3 lymphoma, who are ineligible for high-dose chemotherapy and stem cell transplantation, and who failed front-line regimens containing rituximab. The administration schedule is pixantrone 50 mg/m(2) intravenously (iv.) or gemcitabine 1000 mg/m(2) iv. on days 1, 8 and 15, combined with rituximab 375 mg/m(2) iv. on day 1, up to six cycles. Pixantrone has a conditional European marketing approval for monotherapy in adults with multiple relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. Our trial explores the efficacy of combining pixantrone with rituximab and completes postauthorization measures. TRIAL REGISTRATION NUMBER: NCT01321541.

Item Type: Article
Additional Information: This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/ licenses/by-nc-nd/4.0/
Keywords: DLBCL, aggressive non-Hodgkin lymphoma, gemcitabine, pixantrone, relapse, rituximab, DLBCL, aggressive non-Hodgkin lymphoma, gemcitabine, pixantrone, relapse, rituximab, Oncology & Carcinogenesis, 1112 Oncology And Carcinogenesis
SGUL Research Institute / Research Centre: Academic Structure > Institute of Medical & Biomedical Education (IMBE)
Academic Structure > Institute of Medical & Biomedical Education (IMBE) > Centre for Clinical Education (INMECE )
Journal or Publication Title: Future Oncology
ISSN: 1744-8301
Language: eng
Dates:
DateEvent
1 August 2016Published
11 April 2016Accepted
Publisher License: Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0
PubMed ID: 27093976
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/108174
Publisher's version: https://doi.org/10.2217/fon-2016-0137

Actions (login required)

Edit Item Edit Item